Ocata Therapeutics Inc fka OCAT

[ddls]

They will "try" to avoid a RS if at all possible. But, RS'S have to be put into two categories, 1. those that do it out of necessity to stay on a certain exchange, and 2. those that do it on strength. ACTC would do it on the latter. ACTC will be the next "Google" of biotech, and then some. Here's to ACTC. Cheers!